Form 8-K

8-K — Kyverna Therapeutics, Inc.

Accession: 0001193125-26-168287

Filed: 2026-04-22

Period: 2026-04-22

CIK: 0001994702

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d100817d8k.htm (Primary)

EX-99.1 (d100817dex991.htm)

GRAPHIC (g100817ex99_1p10g1.jpg)

GRAPHIC (g100817ex99_1p11g1.jpg)

GRAPHIC (g100817ex99_1p12g1.jpg)

GRAPHIC (g100817ex99_1p13g1.jpg)

GRAPHIC (g100817ex99_1p14g1.jpg)

GRAPHIC (g100817ex99_1p15g1.jpg)

GRAPHIC (g100817ex99_1p16g1.jpg)

GRAPHIC (g100817ex99_1p17g1.jpg)

GRAPHIC (g100817ex99_1p18g1.jpg)

GRAPHIC (g100817ex99_1p19g1.jpg)

GRAPHIC (g100817ex99_1p1g1.jpg)

GRAPHIC (g100817ex99_1p20g1.jpg)

GRAPHIC (g100817ex99_1p21g1.jpg)

GRAPHIC (g100817ex99_1p22g1.jpg)

GRAPHIC (g100817ex99_1p23g1.jpg)

GRAPHIC (g100817ex99_1p24g1.jpg)

GRAPHIC (g100817ex99_1p25g1.jpg)

GRAPHIC (g100817ex99_1p26g1.jpg)

GRAPHIC (g100817ex99_1p27g1.jpg)

GRAPHIC (g100817ex99_1p28g1.jpg)

GRAPHIC (g100817ex99_1p29g1.jpg)

GRAPHIC (g100817ex99_1p2g1.jpg)

GRAPHIC (g100817ex99_1p30g1.jpg)

GRAPHIC (g100817ex99_1p31g1.jpg)

GRAPHIC (g100817ex99_1p32g1.jpg)

GRAPHIC (g100817ex99_1p33g1.jpg)

GRAPHIC (g100817ex99_1p34g1.jpg)

GRAPHIC (g100817ex99_1p35g1.jpg)

GRAPHIC (g100817ex99_1p36g1.jpg)

GRAPHIC (g100817ex99_1p37g1.jpg)

GRAPHIC (g100817ex99_1p38g1.jpg)

GRAPHIC (g100817ex99_1p3g1.jpg)

GRAPHIC (g100817ex99_1p4g1.jpg)

GRAPHIC (g100817ex99_1p5g1.jpg)

GRAPHIC (g100817ex99_1p6g1.jpg)

GRAPHIC (g100817ex99_1p7g1.jpg)

GRAPHIC (g100817ex99_1p8g1.jpg)

GRAPHIC (g100817ex99_1p9g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d100817d8k.htm · Sequence: 1

8-K

false 0001994702 0001994702 2026-04-22 2026-04-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2026

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41947

83-1365441

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

5980 Horton St., Suite 550

Emeryville, California

94608

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 925-2492

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.00001 per share

KYTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On April 20, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release announcing positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 Phase 2/3 registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with generalized myasthenia gravis (gMG). On April 21, 2026, the Company issued an additional press release announcing positive primary analysis results from its registrational trial, KYSA-8, of miv-cel in stiff person syndrome (SPS). The Company will host a conference call at 7:00 a.m. Eastern Time on April 22, 2026 to review the results announced in the foregoing two press releases (the “Conference Call”). A copy of the slides to be used in connection with the Conference Call is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

d) Exhibits

Exhibit

Number

Description

99.1

Kyverna Therapeutics, Inc. Presentation - Highlighting New Data from Our Neuroimmunology Franchise at AAN, April 22, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KYVERNA THERAPEUTICS, INC.

Date: April 22, 2026

By:

/s/ Marc Grasso, M.D.

Marc Grasso, M.D.

Chief Financial Officer

EX-99.1

Filename: d100817dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1 Highlighting New Data from Our Neuroimmunology Franchise at

Disclaimer and Forward-Looking Statements This presentation contains

forward-looking statements that are based on management’s beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the

“Company”). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements include, but are not limited to, statements concerning: the Company’s

future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, named-patient access data, ongoing clinical trials, research and development

costs, plans for manufacturing, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations. These forward-looking statements are subject to risks and uncertainties, including the

factors described under the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission.

Actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. When evaluating Kyverna’s business and prospects, careful consideration should be given to these risks and uncertainties.

These statements speak only as of the date of this presentation, and Kyverna undertakes no obligation to update or revise these statements. This presentation also contains estimates made by independent parties relating to industry market size and

other data. These estimates involve a number of assumptions and limitations and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information, and we do not take any

responsibility for the accuracy or completeness of such information. This presentation contains references to trademarks and marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this presentation may

appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. The

Company does not intend its use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by any other companies. This presentation includes results from

named-patient basis access. Similar to expanded access or compassionate use in the United States, “IH” or “Individueller Heilversuch,” also known as “named-patient basis access,” is a regulatory scheme in Germany

that allows for the supply of a treatment that has not received marketing authorization for an individual patient in response to a request by the treating physician on behalf of the named patient. This option can be pursued for the expected benefit

of a patient who has exhausted all available treatment options, under the discretion of the treating physician, with the patient’s consent. The use of miv-cel in the IH settings is not a substitute for, or intended to replace, our clinical

trials. The goal is not to assess the effectiveness of a therapy, but rather to provide an individual patient with a possible efficacious approach when all other treatment options have failed, as determined by the patient’s physician. While we

do not expect to be able to use the results from these activities as the basis for approval in our applications for marketing approval to the U.S. Food and Drug Administration (FDA) or other foreign regulatory agencies, we believe such activities

Today’s Agenda Speakers Solidifying our Leadership in Autoimmune

CAR T Stiff Person Syndrome (SPS) – Primary Analysis Review Warner Biddle Naji Gehchan, M.D., MSc, MBA Chief Executive Officer Chief Medical & Development Officer Generalized Myasthenia Gravis (gMG) – Phase 2 Data Update Advancing

Valuable Market Opportunity in SPS Amanda Piquet, M.D., FAAN Sri Muppidi M.D. University of Colorado Anschutz Stanford Medicine Céline Dion Foundation Endowed Chair Q&A ©2026 Kyverna Therapeutics, Inc. 3

Positioned to Deliver the First Approved Autoimmune CAR T, Miv-cel Lead

indications, SPS and gMG, addressing significant unmet medical need Transformative clinical results reinforce potential to change the treatment paradigm by delivering drug-free, disease-free remission with a single dose BLA submission preparations

underway for SPS, a valuable commercial opportunity Phase 3 gMG trial paves way to significant market opportunity underpinned by miv-cel’s differentiated clinical profile ©2026 Kyverna Therapeutics, Inc. 4

New Data Reinforce Kyverna’s Differentiated Neuroimmunology

Franchise Opportunity SPS Registrational Primary Analysis gMG Phase 2 Longer-Term Follow-Up Further supports path to approval & confidence in launch Further supports confidence in Phase 3 Trial ✓ Statistically significant, durable

clinical ✓ Even deeper responses as data mature, with benefit across all endpoints, with reversal durability out to 52 weeks of disability scores ✓ 100% of patients achieved clinically ✓ New secondary endpoint results and

meaningful response across MG-ADL, translational data demonstrate full QMG, and MGC spectrum of miv-cel clinical benefit ✓ Majority of patients achieved MSE 100% free of immunotherapies and a well-tolerated safety profile SPS – 100%

free of immunotherapies for SPS as of Week 16 and through last follow-up. gMG – 100% free of immunotherapies, including NSISTs, high-dose steroids (>10 mg), and FcRn and complement inhibitors up to 24 weeks. MG-ADL, myasthenia gravis

Miv-cel: Potential First-in-Class and Best-in-Class CAR T Designed for

Potency & Tolerability 1,2 Mivocabtagene Autoleucel (miv-cel) • More than 100 patients dosed with Fully Human Autologous CD19 CAR T 3 With CD28 Costim miv-cel across multiple indications • Deep and broad depletion of peripheral-

Anti-CD19 scFv and tissue-resident B cells to support broad 4,5 immune reset and durable remission CD8α Hinge 3 • No high-grade CRS or ICANS CD8α TM • First SPS and gMG patients treated with a single dose of miv-cel achieved

durable CD28 Costim efficacy beyond 24 months without the 6 need for chronic immunotherapies CD3ζ CRS, cytokine release syndrome; Costim, co-stimulation; gMG, generalized myasthenia gravis; ICANS, immune effector cell-associated neurotoxicity

syndrome; scFv, single-chain fragment variable; TM, transmembrane. 1. Brudno JN, et al. Nat Med. 2020;26:270-280. 2. Alabanza L, et al. Mol Ther. 2017;25:2452-2465. 3.Data on file, Kyverna Therapeutics. 4. Minopoulou I, et al. Ann Rheum

SPS – Primary Analysis Results from KYSA-8 Registrational Trial

SPS is a Debilitating, Progressive Autoimmune Disease with No

FDA-Approved Therapies SPS impacts the inhibitory signaling Devastating Impact on Patients pathways, which are the body’s braking system and the target of 80% of patients lose mobility, needing autoantibodies produced by B 1-3 walking aid

assistance or wheelchair 1,2 cells in SPS Only ~19% of patients remained able 4 Symptoms characterized by muscle to work after 4 years stiffness and painful muscle spasms, 1-3 “Freezing attacks” and sudden falls impacting mobility 1,2

requiring ER care Inadequate response with off-label Risk of permanent disability and symptomatic and immunomodulatory 3 increased mortality 1,2,5 therapies ER, emergency room. 1. Rakocevic G, et al. BMC Neurol. 2019;19:1. 2. Dalakas MC. Nat Rev

Neurol. 2024;20(10):587-601. 3. Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165. 4.NCBI. https://www.ncbi.nlm.nih.gov/sites/books/NBK573078/ ©2026 Kyverna Therapeutics, Inc. 9 5. Dalakas MC. Neurol Neuroimmunol Neuroinflamm.

2023;10(3):e200109.

SPS Natural History Study Reinforces Significant Unmet Medical Need

Large, multicenter, retrospective study assessing T25FW in patients with SPS (n=153) Key Takeaways • Majority of patients had no or limited (<20%) improvement in T25FW • Disability (mRS) did not improve over time • Walking aid

use increased over time • All patients treated with off-label immunomodulators or symptomatic medication Study Contextualizes Transformative Miv-cel Data and Supports the T25FW as a Valid Longitudinal Measure of Mobility in SPS Newsome SD, et

Registrational Trial Designed to Support Path to BLA Received Both ODD

and RMAT Designations KYSA-8: Open-label, single-arm, multicenter study N = 26 Primary endpoints: Miv-cel • Age 18 to 75 years • Change from baseline in T25FW at 16 weeks Low-Dose Cy/Flu • Safety • Diagnosis of SPS

lymphodepletion One- • Inadequate response Secondary endpoints: change from + year to immunomodulatory baseline at 16 weeks Single infusion of therapy Follow 8 1×10 CAR T cells • Modified Rankin Scale (mRS) Up • Stiffness

index ≥2 • Distribution of Stiffness Index (DSI) • Hauser Ambulation Index (HAI) • Heightened Sensitivity Scale (HSS) SPS immunotherapies are discontinued Rapid Clinical Enrollment Underscores Significant Unmet Need and

Kyverna’s Ability to Execute Cy/Flu, cyclophosphamide and fludarabine; ODD, Orphan Drug Designation; RMAT, Regenerative Medicine Advanced Therapy; T25FW, timed 25-foot walk test. ©2026 Kyverna Therapeutics, Inc. 11

Primary Endpoint Outcome Assesses Impact of SPS on Walking Ability

Timed 25-Foot Walk (T25FW) 20% improvement 1 • Validated tool to assess walking ability considered clinically 2 1 • Used to evaluate stiffness and loss of mobility in SPS meaningful 3 • Healthy adults can perform the T25FW in ~4-5

seconds T25FW = Average of 2 Walks FIRST WALK TURN AROUND SECOND WALK 25 FEET START/STOP START/STOP 1. Hobart J, et al. Neurology. 2013; 80: 1509-1517. 2. Newsome SD and Johnson T J. Neuroimmunol. 2022;369:577915. 3. Motl RW, et al. Mult Scler J.

Secondary Endpoint Outcomes Assess Extent of Disability and

SPS-Specific Symptoms Modified Rankin Degree of 0 1 2 3 4 5 6 1 disability No symptoms Nonsignificant Slight Moderate Severe Death Moderately Scale (mRS) Disability Disability Disability Disability Severe Disability Hauser Time and degree of

assistance to Ambulation 0 1 2 3 4 5 6 7 8 9 2 No symptoms Fatigue Abnormal gait No Support Unilateral Unilateral Bilateral Cannot walk Restricted to Restricted to complete T25FW T25FW ≤10s T25FW ≤20s support support support 25ft WC WC *

† Index (HAI) T25FW ≤20s T25FW >20s T25FW >20s Frequent WC Can self No self transfer use transfer Distribution-of- Muscle stiffness across body 1 point for each stiff body region (0-6) Stiffness 3,4 regions Index (DSI) Number of

Heightened triggers of 1 point for each trigger/stimulus (1-7) Sensitivity Scale muscle 3,4 (HSS) spasms T25FW, timed 25-foot walk; WC, wheelchair. 1. van Swietin JC, et al. Stroke. 1988; 19(5): 604-607. 2. Hauser SL, et al. New Engl J Med. 1983;

Primary Endpoint Met: Significant Improvement in T25FW 46% Median

Improvement at Week 16 Significant T25FW Improvement and Reduced Walking Aid Use • 81% of patients achieved clinically meaningful improvement (≥20% 1 reduction from baseline) • 31% completed T25FW in <5 seconds; P = .0003 2

typical time for healthy adults • Of the 12 patients requiring a walking aid for T25FW at baseline, 67% (8/12) no longer needed assistance at week 16 • As of week 16 and through last follow- Baseline 35 None 54 12 up, all 26 (100%)

patients remained n=26 Week 16 Unilateral 85 4 12 free of immunomodulatory or n=26 Bilateral 0 20 40 60 80 100 immunosuppressant therapies for SPS* Patients, % *Includes Includes IVIg/SCIg, PLEX, rituximab and/or prednisone (≥20 mg/day) for

SPS symptoms. Data cutoff: 26Nov2025. Percentages may total more than 100% due to rounding. BL, baseline; T25FW, timed 25-foot walk. 14 1. Hobart J, et al. Neurology. 2013;80(16):1509-17. 2. Motl RW, et al. Mult Scler. 2017;23(5):704-710.

Secondary Endpoints Met: Miv-cel Achieved Significant (P < .0001)

Improvements in Disability, Mobility, Stiffness, and Hypersensitivity Modified Rankin Scale Hauser Ambulation Index 0 1 2 3 4 5 6 0 1 2 3 4 5 6 7 8 9 • Significant (P < .0001) mean improvements in mRS and HAI of -0.8 (SD, 0.86) and -1.6

(1.13) and SPS- specific measures, DSI and HSS, of -1.5 (1.75) and -3.2 (2.01), respectively • 96% of patients (25/26) had improvement in ≥1 primary or secondary efficacy endpoint Data cutoff: 26Nov2025. Percentages may total more than

100% due to rounding. 15 BL, baseline; DSI, Distribution-of-Stiffness Index; HAI, Hauser Ambulation Scale; HSS, Heightened Sensitivity Scale; mRS, Modified Rankin Scale; wk, week.

Additional Efficacy Measures: Substantial Improvements in Physical and

Mental Functioning 36-Item Short Form Health Survey (SF-36): 6-Minute Walk Test (MWT): >4-fold improvement Week 16 scores comparable to healthy adults 1 over clinical minimally important change 2,3 for most domains 89-meter median improvement at

week 16 Data cutoff: 26Nov2025. 16 1. Oosterveer DM, et al. Mult Scler Relat Disord. 2022;57:103438. 2. Maglinte GA, et al. J Clin Epidemiol. 2012;65(5):497-502. 3. Wu Q, et al. Medicine (Baltimore). 2023;102(24):e33979.

Robust Miv-cel Expansion Led to Complete Peripheral B-cell Depletion

and Significant Reductions in Autoantibody Titers Robust CAR T-cell Expansion Deep B-cell Depletion Reduced GAD65-IgG P < .0001 Median Median 56% IQR IQR median reduction 750 500 250 0 Baseline Week 16 n=20 n=20 • CAR-positive T cells

peaked by day 14 • 54% of patients had B-cell • GAD65-IgG was reduced reconstitution by week 16 in 19/20 patients with ≥20 nM GAD65 at baseline • Efficacy was maintained with B-cell reconstitution Data cutoff: 26Nov2025. Box

and whisker plots showing median line (dark line), and interquartile range (box), and min/max (bars). 17 CAR, chimeric antigen receptor; IgG, immunoglobulin G; GAD65, glutamic acid decarboxylase 65. GAD65-IgG by RIA, nmol/L

Miv-cel Treatment Induced Markers of Broad Immune Reset B-Cell

Phenotypes Regulatory T Cells Regulatory T Cells Non-Class Switched Class Switched Naïve Memory Memory • Newly emerging B-cell population showed significantly increased • Significant increase in naïve phenotype with concomitant

decrease in memory phenotype regulatory T cells at week 16 Data cutoff: 26Nov2025. Box and whisker plots showing median line (dark line), and interquartile range (box), and min/max (bars). 18 IgD, immunoglobulin D.

Miv-cel Demonstrated a Well-Tolerated Safety Profile • No

high-grade CRS or ICANS observed Treatment-Related Adverse N=26 Events, n (%) • Most common treatment-related AEs were CRS (92%), fatigue (54%), diarrhea (38%), and CRS (any Grade) 24 (92) headache (31%) 10 (38) Grade 1 • 4 patients had

Grade 3/4 neutropenia, an expected AE with lymphodepletion and CAR T-cell therapies Grade 2 14 (54) − All events were manageable with treatment including 3 (12) ICANS (any Grade) G-CSF, fully resolved in 3 patients (median duration of 85

days), and was ongoing in 1 patient Grade 1 3 (12) − No serious infections associated with neutropenia 4 (15) Grade 3/4 neutropenia • Treatment-related serious AEs occurred in 3 patients; Any treatment-related serious AE 3 (12) all fully

resolved without sequalae Data cutoff: 26Nov2025 CRS and ICANS graded using ASTCT criteria; other AEs graded using CTCAE criteria. 19 AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CAR, chimeric antigen

receptor; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; LD, lymphodepletion.

Potential to Achieve Durable, Drug-Free, Disease-Free Remission and

Reverse Disability In KYSA-8 trial, a single dose of miv-cel resulted in: Significant, robust, rapid improvements in mobility, disability, stiffness, and hypersensitivity 100% free of immunomodulatory or immunosuppressive therapies for SPS as of

last follow-up A consistent, well-tolerated, and manageable safety profile, with the potential for outpatient administration Sustained clinical benefit following deep B-cell depletion and broad immune reset ©2026 Kyverna Therapeutics, Inc.

gMG – Updated Data from Phase 2 KYSA-6 Trial Naji Gehchan, M.D.,

Despite Available Treatment Options, High Disease Burden Remains in

Generalized Myasthenia Gravis Current State of Treatment • gMG is a B-cell and antibody-mediated for Patients With gMG neuromuscular autoimmune disease that 3,4 causes fluctuating muscle weakness and Inadequate symptom control 1,2 fatigue Few

reach minimal symptom 1,5-6 expression (MSE) Novel therapies are needed that Majority require ongoing minimize or eliminate symptoms of 1-4 immunosuppressant therapy disease while reducing risks associated with chronic immunosuppression Costly and

chronic treatment 1,7 options 1. Howard Jr JF, et al. Lancet Neurol. 2021;20(7):526-536. 2. Vu T, et al. NEJM Evid. 2022;1(5):EVIDoa2100066. 3. DeHart-McCoyle M, et al. BMJ Med. 2023;2(1):e000241. 4. Dewilde S, et al. BMJ Open. 2023;13(1):e066445.

5. AstraZeneca. ULTOMIRIS® efficacy data from CHAMPION-MG. https://ultomirishcp.com/gmg/efficacy. Accessed 20 Aug 2025. 6. Vu T, et al. AAN 2025. S34.002. 7. Data on File, Kyverna Therapeutics. ©2026 Kyverna Therapeutics, Inc.

KYSA-6: Phase 2/3 Study of Miv-cel in gMG Phase 2 design: Open-label,

single-arm, multicenter study N = 7 • Age 18 to 75 years Miv-cel Primary endpoints • Diagnosis of gMG, Class IIB-IV per MGFA • MG-ADL at 24 weeks criteria Low-Dose Cy/Flu • Adverse events • Autoantibodies to AChR,

18-month lymphodepletion MuSK, or LRP4 + follow up Key secondary endpoints • MG-ADL ≥6 Single infusion of • QMG and MGC scores 8 1×10 CAR T cells • Failed ≥2 immunosuppressive/ • PK/PD immunomodulatory

therapies OR failed ≥1 immunosuppressive therapy and required chronic plasmapheresis or IVIg to control symptoms MG immunotherapies are discontinued Longer-Term Follow-Up Data Cut Off as of February 25, 2026 AchR, acetylcholine receptor;

Cy/Flu, cyclophosphamide and fludarabine; IVIg, Intravenous Immunoglobulin; LRP4, low-density lipoprotein receptor-related protein 4; MG-ADL, myasthenia gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MGFA, Myasthenia Gravis

Miv-cel Demonstrated Rapid and Robust Reductions in MG-ADL and QMG

Sustained Out to 52 Weeks MG-ADL score QMG score Change from BL Change from BL Baseline Baseline Week 2 Week 24 Week 2 Week 24 Mean MG-ADL 10.6 –6.4 –8.5 Mean QMG 16.9 –8.6 –11.3 Data cutoff: February 25, 2026. 25 BL,

baseline; MG-ADL, myasthenia gravis activities of daily living; QMG, quantitative myasthenia gravis.

After a Single Dose of Miv-cel, Patients Achieved Substantial and

Clinically Meaningful Reductions in MG Outcome Scores and Treatment Burden Substantially improved clinical outcomes MG-ADL QMG 100% had clinically meaningful response 100% had clinically meaningful response (≥3-point reduction vs baseline)

(≥2-point reduction vs baseline) 100% were responders MGC (≥3-point reduction vs baseline) 100% had clinically meaningful response 57% reached MSE at last follow-up (≥3-point reduction vs baseline) (MG-ADL score of 0-1) –16.0

mean reduction at 24 weeks Substantially reduced MG treatment burden 100% free of immunotherapies, including NSISTs, high-dose steroids (>10 mg), and FcRn and complement inhibitors up to 24 weeks 6 of 7 patients remained free of these agents at

last follow-up Data cutoff: February 25, 2026. 26 BL, baseline; FcRn, neonatal fragment crystallizable receptor; MG-ADL, myasthenia gravis activities of daily living; MGC, Myasthenia Gravis Composite; MSE, minimal symptom expression; NSIST,

nonsteroidal immunosuppressive therapy; QMG, quantitative myasthenia gravis.

Miv-cel Demonstrated a Well-Tolerated Safety Profile • No

high-grade CRS and no ICANS observed Treatment-related AEs, n (%) Patients (n=7) • CRS was low-grade and manageable in all patients CRS (any grade) 7 (100) − 5 of 7 patients only experienced fever Grade 1 5 (71) (grade 1 CRS) Grade 2 2

(29) • 2 patients with Grade 3/4 treatment-related AEs ICANS (any grade) 0 (0) of neutropenia; an expected AE with 3 (43) Grade 3/4 events lymphodepletion and CAR T-cell therapies; 2 (29) Neutropenia neither was associated with

infections − 1 patient had transient Grade 4 neutropenia that Lymphopenia 1 (14) resolved within 10 days post-infusion Lymphocyte count decreased 1 (14) − 1 patient had Grade 4 neutropenia was manageable a SAE (any grade) 0 (0)

with G-CSF, and resolved within 2 months post- infusion Data cutoff: February 25, 2026. a After the prior data cut (October 3, 2025), a previously reported treatment-related SAE was reclassified by the Investigator as 'not serious’, reflecting

his clinical assessment of the AE per protocol-defined seriousness criteria. CRS and ICANS graded using ASTCT criteria; other AEs graded using CTCAE criteria. AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CAR,

chimeric antigen receptor; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; DLT, dose-limiting toxicity; G-CSF, granulocyte colony- 27 stimulating factor; ICANS, immune effector cell-associated neurotoxicity

syndrome; LD, lymphodepletion; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

Robust CAR T-cell Expansion Led to Deep B-cell Depletion Robust CAR

T-cell expansion Deep B-cell depletion • B-cell recovery was detected in 2 patients at weeks 12 and 16, respectively Data cutoff: February 25, 2026. 28 BL, baseline.

Miv-cel Reduced Autoantibody Levels While Preserving Humoral Immune

Responses Reduction of autoantibodies Preservation of humoral immunity Autoantibody Ref Range BL Last visit (Wk) AChR, nmol/L Neg: ≤ 0.3 5.6 0.8 (Wk 52) 20 AChR, nmol/L Neg: ≤ 0.3 71.5 0.7 (Wk 52) MuSK, 1:X Neg: < 1:10 1:1280 1:10 (Wk

12) 0 -25 -50 -75 -100 AChR MuSK BL0 6 12 18 24 30 36 42 48 52 Visit, weeks post-infusion Data cutoff: February 25, 2026. Humoral immunity data was not available for patient 7; dashed line on humoral immunity graph shows the threshold above which

indicates prior exposure or vaccination. 29 AChR, acetylcholine receptor; BL, baseline; IgG, immunoglobulin G; MuSK, muscle-specific kinase; neg, negative value; Ref, reference; Wk, week.. Autoantibodies Percent Change from Baseline, %

Potential to Change the gMG Treatment Paradigm by Delivering Durable,

Drug-Free, Disease-Free Remission In KYSA-6 trial, a single dose of miv-cel resulted in: Robust, rapid, and sustained improvements regardless of prior biologic exposure 100% free of immunotherapies, including NSISTs, high-dose steroids (>10 mg),

and FcRn and complement inhibitors up to 24 weeks Consistent, well-tolerated, and manageable safety profile with no high-grade CRS or ICANS Evidence of immune reset and preserved humoral immunity CRS, cytokine release syndrome; FcRn, neonatal

Phase 3 Trial Advancing with First Patients Enrolled and 14 Sites

Activated Globally ~60-patient, global, open-label, randomized controlled Phase 2/3 trial with crossover design Co-Primary Endpoints (MG-ADL & QMG) Miv-cel Low-Dose Cy/Flu lymphodepletion + Screening, 8 Single infusion of 1×10 CAR T cells

Follow Up N = ~60 washout, MG immunotherapies are discontinued apheresis, and Randomized Miv-cel resume standard 1:1 Follow Up Standard of Care Crossover of care Traditional agents or complement pathway inhibitors 24 weeks Baseline 18 Measurement

Months Standard of care may consist of traditional agents (e.g., prednisone, azathioprine, mycophenolate, methotrexate, chronic IVIG/PLEX) or complement pathway inhibitors (e.g., eculizumab, ravulizumab). Anti-CD20 or -CD19 monoclonal antibodies or

FcRn inhibitors not allowed as defined in inclusion criteria. Cy/Flu, cyclophosphamide and fludarabine; FcRn, neonatal fragment crystallizable receptor; IVIG, Intravenous Immunoglobulin; MG-ADL, myasthenia gravis activities of daily living; PLEX,

Single Dose Miv-cel Achieved Unprecedented gMG Clinical Outcomes

Approved Investigational* All other therapies require chronic background immunotherapies Miv-cel FcRn Complement CD19 BCMA mRNA 1 2,3 4 5 Inhibitor Inhibitor mAb CAR T CD19 CAR T VYVGART® ULTOMIRIS® UPLIZNA® Descartes-08 (KYSA-6, n=6)

4 weeks 6 months 6 months 3 months 6 months Primary Endpoint MG-ADL Reduction ~4.6 3.1 4.2 4.1 8.5 Depth of Response Mean reduction from baseline to primary endpoint QMG Reduction ~6.2 2.8 4.8 3.9 11.3 (non-placebo adjusted) % Responders ~73% ~57%

69% 64% 100% Patients with ≥3-point MG-ADL improvement from baseline to primary endpoint (non-placebo adjusted) Achieve Minimal Symptom Expression 40% 43% Not reported 33% 57% (MSE) At any point before At any point before primary endpoint 6

months to 1 year % of patients achieving MG-ADL of 0 or 1 primary endpoint Note: These observations are derived from separate clinical settings; comparisons across trials are not based on head-to-head studies. BCMA, b-cell maturation antigen; FcRn,

neonatal fragment crystallizable receptor; mAb, monoclonal antibody; MG-ADL, myasthenia gravis activities of daily living; mRNA, messenger RNA; QMG, quantitative myasthenia gravis score. *Under investigation in gMG. © 2025 Kyverna Therapeutics,

Inc. | Confidential – Internal Use Only 32 1. Howard Jr JF, et al. Lancet Neurol. 2021;20(7):526-536. 2. Vu T, et al. NEJM Evid. 2022;1(5):EVIDoa2100066. 3. AstraZeneca. ULTOMIRIS® efficacy data from CHAMPION-MG.

https://ultomirishcp.com/gmg/efficacy. Accessed 20 Aug 2025. 4. Nowak RJ, et al. N Engl J Med. 2025;392(23):2309-2320. 5. Vu T, et al. Nat Med. 2026;32:1131-1141.

Advancing Valuable Market Opportunity in SPS Warner Biddle –

Miv-cel: Potential to Be First and Only Approved Therapy in SPS with

Patients Ready for an Effective Treatment Option Miv-cel 2,3 Addressable Market Initial Total Miv-cel ~6k Priority Addressable Market U.S. Diagnosed 1,2 ~2.0 to 2.5k Patients ~5.5k Patients SPS Patients 30-40% of total diagnosed 90% of total

diagnosed Patients treated with Patients treated with off-label immunotherapy* symptomatic therapies *Immunotherapy defined as off-label immunosuppressants (e.g., prednisone), rituximab and/or IVIg. IVIg, intravenous immunoglobulin. ©2026

Kyverna Therapeutics, Inc. 34 1. Crane PD, et al. Neurology. 2024;103(12):e210078. 2. Analysis of 2024 Komodo U.S. Claims Data. 3. Kyverna Patient Journey and Demand Study (data on file).

SPS Treaters Show Strong Enthusiasm for Early Adoption of Miv-cel

Survey of 20 high volume Product profile based on SPS treaters in U.S. miv-cel topline data 80% view efficacy data 90% view profile as 85% would use miv-cel and one-time treatment compelling versus current for moderate-to-severe as key attributes

Focused Launch Strategy Targets ~10 High-Value SPS Centers •

Thought leaders / high-volume treaters SPS Leadership • Institutional support for miv-cel • Existing patients ready at center Addressable Patients • Strong referral network • Commercial CAR T experience CAR T Expertise

• Accreditation • Robust inpatient and outpatient models Economic Potential • Commercial payer and Medicare dynamics Meaningful Portion of Immediately Addressable Patients at ~10 Centers PPS, Prospective Payment System. ©2026

Kyverna Therapeutics, Inc. 36

Kyverna: Delivering the Curative Potential of CAR T in Autoimmune

Diseases Best-in-Class Profile CAR T Leadership Focused Strategy Demonstrated durable drug- Potentially first approved Neuroimmunology-led free, disease-free remission autoimmune CAR T franchise Pipeline-in-a-Product Strong Financial Position

Valuable Commercial Clinical data supports Supporting SPS BLA submission, Opportunity in SPS expansion into broader anticipated commercial launch Immediately addressable indications and gMG Phase 3 trial market and premium pricing potential

Warner Biddle Marc Grasso, M.D. Naji Gehchan, M.D., MSc, MBA Chief

Executive Officer Chief Financial Officer Chief Medical & Development Officer Q&A Amanda Piquet, M.D., FAAN Sri Muppidi M.D. University of Colorado Anschutz Stanford Medicine Céline Dion Foundation Endowed Chair ©2026 Kyverna

Therapeutics, Inc.

GRAPHIC

Filename: g100817ex99_1p10g1.jpg · Sequence: 6

Binary file (286908 bytes)

Download g100817ex99_1p10g1.jpg

GRAPHIC

Filename: g100817ex99_1p11g1.jpg · Sequence: 7

Binary file (307623 bytes)

Download g100817ex99_1p11g1.jpg

GRAPHIC

Filename: g100817ex99_1p12g1.jpg · Sequence: 8

Binary file (250125 bytes)

Download g100817ex99_1p12g1.jpg

GRAPHIC

Filename: g100817ex99_1p13g1.jpg · Sequence: 9

Binary file (289673 bytes)

Download g100817ex99_1p13g1.jpg

GRAPHIC

Filename: g100817ex99_1p14g1.jpg · Sequence: 10

Binary file (319198 bytes)

Download g100817ex99_1p14g1.jpg

GRAPHIC

Filename: g100817ex99_1p15g1.jpg · Sequence: 11

Binary file (308477 bytes)

Download g100817ex99_1p15g1.jpg

GRAPHIC

Filename: g100817ex99_1p16g1.jpg · Sequence: 12

Binary file (317648 bytes)

Download g100817ex99_1p16g1.jpg

GRAPHIC

Filename: g100817ex99_1p17g1.jpg · Sequence: 13

Binary file (329092 bytes)

Download g100817ex99_1p17g1.jpg

GRAPHIC

Filename: g100817ex99_1p18g1.jpg · Sequence: 14

Binary file (283788 bytes)

Download g100817ex99_1p18g1.jpg

GRAPHIC

Filename: g100817ex99_1p19g1.jpg · Sequence: 15

Binary file (296532 bytes)

Download g100817ex99_1p19g1.jpg

GRAPHIC

Filename: g100817ex99_1p1g1.jpg · Sequence: 16

Binary file (304018 bytes)

Download g100817ex99_1p1g1.jpg

GRAPHIC

Filename: g100817ex99_1p20g1.jpg · Sequence: 17

Binary file (257628 bytes)

Download g100817ex99_1p20g1.jpg

GRAPHIC

Filename: g100817ex99_1p21g1.jpg · Sequence: 18

Binary file (187172 bytes)

Download g100817ex99_1p21g1.jpg

GRAPHIC

Filename: g100817ex99_1p22g1.jpg · Sequence: 19

Binary file (44489 bytes)

Download g100817ex99_1p22g1.jpg

GRAPHIC

Filename: g100817ex99_1p23g1.jpg · Sequence: 20

Binary file (339089 bytes)

Download g100817ex99_1p23g1.jpg

GRAPHIC

Filename: g100817ex99_1p24g1.jpg · Sequence: 21

Binary file (288089 bytes)

Download g100817ex99_1p24g1.jpg

GRAPHIC

Filename: g100817ex99_1p25g1.jpg · Sequence: 22

Binary file (267481 bytes)

Download g100817ex99_1p25g1.jpg

GRAPHIC

Filename: g100817ex99_1p26g1.jpg · Sequence: 23

Binary file (373007 bytes)

Download g100817ex99_1p26g1.jpg

GRAPHIC

Filename: g100817ex99_1p27g1.jpg · Sequence: 24

Binary file (323251 bytes)

Download g100817ex99_1p27g1.jpg

GRAPHIC

Filename: g100817ex99_1p28g1.jpg · Sequence: 25

Binary file (201850 bytes)

Download g100817ex99_1p28g1.jpg

GRAPHIC

Filename: g100817ex99_1p29g1.jpg · Sequence: 26

Binary file (289446 bytes)

Download g100817ex99_1p29g1.jpg

GRAPHIC

Filename: g100817ex99_1p2g1.jpg · Sequence: 27

Binary file (511288 bytes)

Download g100817ex99_1p2g1.jpg

GRAPHIC

Filename: g100817ex99_1p30g1.jpg · Sequence: 28

Binary file (274545 bytes)

Download g100817ex99_1p30g1.jpg

GRAPHIC

Filename: g100817ex99_1p31g1.jpg · Sequence: 29

Binary file (318374 bytes)

Download g100817ex99_1p31g1.jpg

GRAPHIC

Filename: g100817ex99_1p32g1.jpg · Sequence: 30

Binary file (329639 bytes)

Download g100817ex99_1p32g1.jpg

GRAPHIC

Filename: g100817ex99_1p33g1.jpg · Sequence: 31

Binary file (161459 bytes)

Download g100817ex99_1p33g1.jpg

GRAPHIC

Filename: g100817ex99_1p34g1.jpg · Sequence: 32

Binary file (264003 bytes)

Download g100817ex99_1p34g1.jpg

GRAPHIC

Filename: g100817ex99_1p35g1.jpg · Sequence: 33

Binary file (248333 bytes)

Download g100817ex99_1p35g1.jpg

GRAPHIC

Filename: g100817ex99_1p36g1.jpg · Sequence: 34

Binary file (246327 bytes)

Download g100817ex99_1p36g1.jpg

GRAPHIC

Filename: g100817ex99_1p37g1.jpg · Sequence: 35

Binary file (272494 bytes)

Download g100817ex99_1p37g1.jpg

GRAPHIC

Filename: g100817ex99_1p38g1.jpg · Sequence: 36

Binary file (181198 bytes)

Download g100817ex99_1p38g1.jpg

GRAPHIC

Filename: g100817ex99_1p3g1.jpg · Sequence: 37

Binary file (188347 bytes)

Download g100817ex99_1p3g1.jpg

GRAPHIC

Filename: g100817ex99_1p4g1.jpg · Sequence: 38

Binary file (272488 bytes)

Download g100817ex99_1p4g1.jpg

GRAPHIC

Filename: g100817ex99_1p5g1.jpg · Sequence: 39

Binary file (342075 bytes)

Download g100817ex99_1p5g1.jpg

GRAPHIC

Filename: g100817ex99_1p6g1.jpg · Sequence: 40

Binary file (291124 bytes)

Download g100817ex99_1p6g1.jpg

GRAPHIC

Filename: g100817ex99_1p7g1.jpg · Sequence: 41

Binary file (67060 bytes)

Download g100817ex99_1p7g1.jpg

GRAPHIC

Filename: g100817ex99_1p8g1.jpg · Sequence: 42

Binary file (217993 bytes)

Download g100817ex99_1p8g1.jpg

GRAPHIC

Filename: g100817ex99_1p9g1.jpg · Sequence: 43

Binary file (335834 bytes)

Download g100817ex99_1p9g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 45

v3.26.1

Document and Entity Information

Apr. 22, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001994702

Document Type

8-K

Document Period End Date

Apr. 22, 2026

Entity Registrant Name

Kyverna Therapeutics, Inc.

Entity Incorporation State Country Code

Entity File Number

001-41947

Entity Tax Identification Number

83-1365441

Entity Address, Address Line One

5980 Horton St.

Entity Address, Address Line Two

Suite 550

Entity Address, City or Town

Emeryville

Entity Address, State or Province

Entity Address, Postal Zip Code

94608

City Area Code

(510)

Local Phone Number

925-2492

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, par value $0.00001 per share

Trading Symbol

KYTX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration